Clinical trial
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With…
NCT00468039 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00468039 |
|---|---|
| Title | A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin |
| Official title | A Multicenter, Open-label Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin 100mg qd Plus Metformin 1000mg Bid in Drug Naive Patients With Type 2 Diabetes With Very Poor Glycemic Control |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | vildagliptin + metformin |
| Enrollment | 94 |
| Start date | Mar 6, 2007 |
| Primary completion | Jun 6, 2008 |
| Completion | Jun 6, 2008 |
| First posted | May 1, 2007 |
| Last update posted | Dec 19, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: